Sunday 25 October 2020
Home      All news      Contact us      RSS     
healtheuropa - 2 month ago

First medicine to prolong survival in patients with chronic kidney disease

In a groundbreaking Phase III trial AstraZeneca’s Farxiga has shown reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease. Detailed results from the Phase III DAPA-CKD trial have shown that AstraZeneca’s Farxiga (dapagliflozin) reduced the composite measure of worsening of renal function or risk of cardiovascular [ ] The post First medicine to prolong survival in patients with chronic kidney disease appeared first on Health Europa.


Latest News
Hashtags:   

First

 | 

medicine

 | 

prolong

 | 

survival

 | 

patients

 | 

chronic

 | 

kidney

 | 

disease

 | 

Sources